Boosting anticancer vaccines: Too much of a good thing?

摘要

Using both transplantable and oncogene-driven autochthonous tumor modelschallenged with dendritic cell-based vaccines, we have recently found thatboosting provides a clear advantage in prophylactic settings, unless performed onan excessively tight schedule, which causes the loss of central memory T cells.In therapeutic settings, boosting turned out to be always detrimental.